Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2

Conditions

Carcinoma, Non-Small-Cell Lung 17Carcinoma, Hepatocellular 8Nasopharyngeal Carcinoma 7Recurrence 6Neoplasms 6Esophageal Neoplasms 6Breast Neoplasms 6Stomach Neoplasms 5Neoplasm Metastasis 5Esophageal Squamous Cell Carcinoma 5Colorectal Neoplasms 5Locally Advanced Rectal Cancer 4Carcinoma, Renal Cell 4Urinary Bladder Neoplasms 3Small Cell Lung Carcinoma 3Sarcoma 3Rectal Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leukemia, Myeloid, Acute 2Hyperthermia 2Chondrosarcoma 2Carcinoma, Transitional Cell 2

Interventions

Filgrastim 4Ifosfamide 3Carboplatin 3Peripheral Blood Stem Cell Transplantation 2Immune Checkpoint Inhibitors 2Etoposide 2spartalizumab 1regorafenib 1perifosine 1pegfilgrastim 1pazopanib 1ivosidenib 1etoposide phosphate 1enasidenib 1drozitumab 1angiotensin I (1-7) 1alanosine 1abemaciclib 1Vincristine 1Trabectedin 1Topotecan 1Thiotepa 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Image-Guided 1Radiotherapy, Conformal 1Radiotherapy 1Radiosurgery 1Proton Therapy 1Pharmacogenomic Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Chondrosarcoma × Immune Checkpoint Inhibitors × Clear all
NCT04673942 2024-10-26

BETA-PRIME

EpicentRx, Inc.

Phase 2 Recruiting
140 enrolled
Sarcoma

Adenoviridae Infections, Chondrosarcoma, Neoplasms, Sarcoma

NCT05193188 2023-02-16

A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade Chondrosarcoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
70 enrolled
Sarcoma

Chondrosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡